Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance
Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance
Menu
CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and pertuzumab, triggers sustained senescence: new data from a Michelangelo Foundation study.
Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did not increase the rate of pathological complete remission, mostly influenced by PD-L1 expression.
NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as neoadjuvant therapy, with a relevant effect on Ki67
Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a review published on Nature Reviews – Clinical Oncology highlights the state of the art therapy in triple-negative breast cancer
Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance
Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP
HER2+ and ER+ breast cancer, promising results with trastuzumab, pertuzumab
Triple negative breast cancer, new therapeutic options and future strategies
One of the key questions surrounding online dating is whether
Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance
Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP
HER2+ and ER+ breast cancer, promising results with trastuzumab, pertuzumab
Triple negative breast cancer, new therapeutic options and future strategies
One of the key questions surrounding online dating is whether
